Rehabtronics Receives $1.25 Million from Genome BC to Enable Free Quality Improvement Trials of Prelivia
Rehabtronics is pleased to announce that Genome BC is providing $1.25 million to support commercialization of Prelivia, the world’s first neuroscience-based technology designed to protect patients against deadly pressure injuries…